PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
Funding and Cash Runway
PYC Therapeutics completed a $146m Entitlement Offer, extending its cash runway to over $200m. The company is now funded until CY2027, ensuring support for multiple critical human data read-outs within its pipeline.
Pipeline Progress
The company’s third drug development program for polycystic kidney disease has progressed into human trials. Additionally, PYC will present Phase 1/2 data for its Retinitis Pigmentosa drug candidate in May 2025, alongside other near-term human efficacy read-outs.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
